BM progression is a unique disease progression pattern with insufficient response to anti-tumor drugs and poor prognosis because of the active blood–brain barrier (BBB); it accounts for approximately 40% of prior generation EGFR-TKI-resistant metastasis sites (37, 38). This evidence concerns the gene EGFR and neoplasm.